This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignees: University of Notre Dame Du Lac, Cornell University. Active years: 1996-2016.
Company Filing History:
4 out of 385 
1 out of 2,948 
Years Active: 1996-2016
Title: Paul Helquist: Innovator in Therapeutic Agents
Introduction
Paul Helquist is a notable inventor based in Granger, Indiana, who has made significant contributions to the field of therapeutic agents. With a total of 4 patents, his work primarily focuses on addressing lysosomal storage disorders, particularly Niemann-Pick type C disease.
Latest Patents
One of Helquist's latest patents is titled "Histone deacetylase inhibitors as therapeutic agents for Niemann-Pick type C disease." This invention relates to methods of treating lysosomal storage disorders using inhibitors of histone deacetylases, specifically class 1 histone deacetylases. Another significant patent is "Process for preparing histone deacetylase inhibitors and intermediates thereof." This patent outlines a process for preparing unsaturated esters that serve as intermediates for HDAC inhibitors.
Career Highlights
Throughout his career, Paul Helquist has worked with prestigious institutions such as the University of Notre Dame and Cornell University. His research has contributed to advancements in therapeutic methods for complex diseases.
Collaborations
Helquist has collaborated with notable colleagues, including Carlo Cocito and Frederick Maxfield, enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Paul Helquist's innovative work in developing therapeutic agents showcases his dedication to addressing critical health challenges. His contributions continue to influence the field of medical research and treatment options.